Sight Sciences Inc SGHT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
-
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance
-
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
-
Oracle's stock slumps, Apple shares are flat and other stocks on the move
-
Sight Sciences' stock tumbled 32% premarket after revenue warning
Trading Information
- Previous Close Price
- $6.43
- Day Range
- $6.56–6.82
- 52-Week Range
- $1.04–8.45
- Bid/Ask
- $6.56 / $7.24
- Market Cap
- $330.52 Mil
- Volume/Avg
- 113,259 / 212,132
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.07
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 214
- Website
- https://www.sightsciences.com
Comparables
Valuation
|
Metric
|
SGHT
|
ATEC
|
SIBN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.24 | 45.31 | 3.47 |
Price/Sales | 4.07 | 1.37 | 3.73 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SGHT
|
ATEC
|
SIBN
|
|---|---|---|---|
Quick Ratio | 10.39 | 1.08 | 7.99 |
Current Ratio | 11.01 | 2.22 | 9.17 |
Interest Coverage | −9.17 | −8.06 | −12.97 |
Quick Ratio
SGHT
ATEC
SIBN
Profitability
|
Metric
|
SGHT
|
ATEC
|
SIBN
|
|---|---|---|---|
Return on Assets (Normalized) | −22.80% | −9.32% | −6.03% |
Return on Equity (Normalized) | −31.99% | −562.13% | −8.10% |
Return on Invested Capital (Normalized) | −22.08% | −8.81% | −8.97% |
Return on Assets
SGHT
ATEC
SIBN
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Psvnsgbzw | Hgbxd | $196.1 Bil | |||
| Stryker Corp
SYK
| Qppryslz | Dnw | $137.7 Bil | |||
| Boston Scientific Corp
BSX
| Mbbcygs | Jbksk | $122.3 Bil | |||
| Medtronic PLC
MDT
| Yplmxpt | Kxbwpv | $114.7 Bil | |||
| Edwards Lifesciences Corp
EW
| Yckrmcnwym | Nvgcr | $39.6 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Vbbcc | Bknp | $29.3 Bil | |||
| DexCom Inc
DXCM
| Ttdrsqhsl | Jlw | $27.1 Bil | |||
| Steris PLC
STE
| Rpnnrpd | Dytxmc | $23.3 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Bvwvlskps | Wzq | $21.9 Bil | |||
| Insulet Corp
PODD
| Fjwwdjfbl | Dptcx | $16.5 Bil |
United States